Articles tagged with Eye Diseases
The study projects that vision loss from eye diseases will reach 5.5 million Americans by 2020, with age-related macular degeneration, glaucoma, and cataract being the most common causes. Regular comprehensive eye exams are crucial for preventing and/or delaying eye disease in those at higher risk.
A study by the Eye Diseases Prevalence Research Group found that approximately two-fifths of persons aged 40 and older with DM are affected by diabetic retinopathy, while one in twelve have reached a vision-threatening stage. The prevalence rates were estimated using data from eight population-based eye surveys.
The study found that approximately one-third of people older than 40 experience vision disturbances, with myopia being the most prevalent eye disorder. The estimated prevalence rates for myopia vary by region, affecting about one in four people in the US and Western Europe, and one in six Australians.
This April 2004 journal from the American Academy of Ophthalmology presents numerous studies on eye conditions such as Mohs surgery, glaucoma intervention, cataract surgery outcomes, and more. The research findings cover a range of topics including diabetic macular edema diagnosis, retinal detachment, and keratoconic corneas.
Scientists identify site-specific growth signals that promote capillary formation in the developing retina and inner ear, providing a potential new approach for treating blinding diseases and improving treatment outcomes for conditions like cancer, heart disease, and stroke.
Scientists have discovered a key relationship between two inherited eye disorders, Norrie disease and FEVR, linked to blood vessel malformation and activation of the Wnt pathway. The study sheds light on potential treatments for these conditions and raises questions about specialized vascular development systems in other tissues.
A study of 5,924 participants aged 43 to 84 found that dry eye developed in 13.3% over a five-year period, with significant associations with age, allergy or diabetes, and poorer health. Certain medications and lifestyle factors also showed protective effects.
Research on glaucoma medication latanoprost vs. timolol shows intraocular pressure-reducing effects and safety benefits. A study on frequency-doubling perimetry also explores its feasibility in young children.
Children with optic nerve disease are up to 20 times more likely to experience excessive daytime sleepiness due to disruptions in their body's internal clock. Researchers found that the loss of a specific type of cell in the retina, which helps regulate light exposure, is directly linked to sleep disturbances.
Research suggests eye disease is a risk factor for sleep disorders, particularly in patients with optic nerve disease. The study found that visually impaired subjects with optic nerve disease were nine times more likely to experience pathologic sleepiness than those with normal sight.
Scientists are working to create an animal that lacks the genomic architecture to code for normal prions, which cause Bovine Spongiform Encephalopathy (BSE) and Creutzfeldt-Jacob Disease. The goal is to produce a cow that is genetically incapable of producing prions, which could potentially contain the risks of this disease.
This issue of the January 2004 Ophthalmology journal presents a range of studies on LASIK complications, including night vision issues and corneal epithelial adhesion abnormalities. Researchers also explore various eye diseases, such as retinal tears, glaucoma, and macular degeneration.
The American Academy of Ophthalmology published various studies on cataract surgery, glaucoma treatment, and eye diseases in December 2003. These studies examined the effectiveness of different surgical techniques and medications for treating refractive errors, glaucoma, and age-related macular degeneration.
The American Academy of Ophthalmology meeting explored approaches to preventing, treating, and living with macular degeneration. Researchers presented updates on the effect of vitamin and mineral supplementation, surgical approaches, anti-VEGF drugs like Macugen, and visual rehabilitation.
A recent study suggests that daily vitamin supplements can reduce the risk of advanced age-related eye disease (AMD) by 25% and vision loss by 19%. Researchers estimate that 1.3 million adults may develop advanced AMD without treatment, highlighting the importance of regular retina exams.
Researchers are developing a new drug to treat myasthenia gravis by targeting the nerve-muscle communication point and reducing complement activation. The study aims to provide a more effective treatment with fewer side effects than existing therapies, which have limited success due to their adverse effects.
A study found that people with glaucoma and macular degeneration had lower rates of annual eye exams compared to those with diabetes. The study suggests that changes in medical practice are necessary to improve patient compliance and prevent visual loss.
Researchers have found that injecting adult bone marrow-derived stem cells into the back of mouse eyes curtails retinal degeneration and restores normal retinal tissue. The treated mice had improved vision and responded to light, offering a potential new approach for treating retinitis pigmentosa.
A study published in the American Journal of Ophthalmology found that nearly 3.2 million women aged 50 and older in the US suffer from debilitating dry eye syndrome, which can lead to scarring, ulceration, and loss of vision. The disease is more common in women than men, with Hispanic and Asian women experiencing more severe symptoms.
Researchers have discovered a gene mutation associated with an eye disease that resembles age-related macular degeneration. The study, led by Michigan Medicine scientists, has found that the mutation in RDS can be inherited in an autosomal dominant pattern, affecting central vision and leading to permanent loss of vision.
CA4P, a vascular targeting agent, is being tested in humans for the first time to prevent and regress choroidal neovascularization, a major cause of vision loss in age-related macular degeneration. The trial is led by Johns Hopkins' Wilmer Eye Institute and funded by The Foundation Fighting Blindness, Inc.
Researchers use eye movement tests to investigate brain abnormalities causing mental disorders, including schizophrenia, depression, and autism. The study aims to develop a noninvasive tool for diagnosing brain disorders.
Researchers developed VEGF-TRAP, an injection that prevents new blood vessel growth in the eyes of mice. The treatment halted existing vessel leakage and showed long-lasting effects without complications. It may offer a potential treatment for diabetic retinopathy and macular degeneration.
Researchers found that model mice with pigment dispersion glaucoma had abnormal immune responses in their eyes, which preceded disease onset. The study suggests that loss of immune privilege may trigger the development of glaucoma.
A new study finds that patching the unaffected eye for two hours daily is as effective as patching for six hours in treating moderate amblyopia in children. The results improve visual acuity and reduce social stigma associated with treatment, making it easier for parents to monitor their child's progress.
Children with moderate amblyopia showed significant improvement in vision after four months of daily two-hour or six-hour patching. This study provides real scientific evidence for a more convenient treatment option, reducing social stigma associated with traditional patching methods.
Schepens Eye Research Institute scientists have discovered a new drug that can trap abnormal growth factors in the cornea, potentially improving corneal transplants. Additionally, a gene therapy approach has shown promise in preventing and treating autoimmune diseases like uveitis by inducing a protein called a-MSH.
A comprehensive five-year study tracked causes of blindness and access to eye care among the US Latino population, finding high rates of vision-related problems. The study revealed that Latinos have nearly 18% vision impairment by age 85 and older, with diabetes and cataracts being leading causes.
A recent study by David Heeger and David Ress of NYU found that brain activity in the visual cortex corresponds to subjects' precepts, not the physically presented stimulus. This suggests that distortions occur at the first stages of brain processing and may shed light on conditions like amblyopia.
A long-term study found that administering oral antivirals reduced the risk of blindness and other serious eye effects in patients with eye shingles. Untreated patients experienced 8.9% adverse outcomes, while treated patients had only 2.1%. Timing of treatment also affected long-term outcomes.
Using adaptive optics, researchers can now clearly see features such as blood flow in the retina, enabling early diagnosis of diseases. This technology will help eye doctors track changes in patients with conditions like diabetes and glaucoma.
Researchers found that low-level lead exposure during development in mice injures and kills rod-shaped photoreceptor cells, a crucial component of human vision. The study suggests possible treatments using an anti-death protein called Bcl-xL to prevent cell death in eye disorders.
Researchers have developed a new technology using adaptive optics to improve diagnosis of eye diseases. The technology enables doctors to see individual cells in the retina, allowing for early detection and treatment of conditions such as glaucoma and age-related macular degeneration.
A new study from the Liverpool Diabetic Eye Study has proposed optimal screening intervals for diabetic eye disease, based on incidence data. The findings suggest that patients with no baseline retinopathy should be screened every 3 years, while those with background retinopathy can be screened annually.
Researchers have discovered a protein in the eye that can successfully treat an autoimmune disease by converting conventional T cells into regulatory T cells. The study found significant reduction in uveitis severity and prevention of disease onset in mice models.
A six-week self-management program has been shown to enhance the quality of life and reduce depression in patients with age-related macular degeneration. The program, which includes group sessions and problem-solving skills, improved patients' confidence and ability to cope with their vision loss.
Researchers found that treating people with early-stage glaucoma immediately can delay disease progression and slow vision loss. The study followed 255 patients with early stage glaucoma in at least one eye, finding that treatment led to a slower rate of disease progression.
Researchers seek compounds to inhibit angiogenesis, a common cause of vision loss. A new class of anti-angiogenic molecules has shown promise in pre-clinical studies, with 70% inhibition in 100% of cases.
Researchers have identified a missing piece of DNA as the cause of Facioscapulohumeral Muscular Dystrophy (FSHD), allowing nearby genes to become overactive. This discovery provides a starting point for developing therapeutic tools and offers hope for patients, who often suffer from progressive muscle loss and severe disability.
Researchers have discovered a gene associated with both macular degeneration and retinitis pigmentosa, two eye diseases affecting different segments of vision. The RPGR gene is linked to early-onset macular degeneration primarily affecting males.
Researchers at TSRI have developed a technique to selectively deliver adult stem cells into the eye, which can stimulate vessel growth and address inherited retinal degenerations. The cells can incorporate into the vasculature and make it normal, or be loaded with antiangiogenics to selectively wipe out the formation of new blood vessels.
Nearly a third of surveyed glaucoma patients reported difficulties with taking multiple medications, citing missed dosing and inadequate waiting periods. Physicians advocate for more patient education and convenient treatments to improve compliance and vision outcomes.
Brown University researchers will develop a research-based register of controlled trials related to ophthalmology and optometry. They aim to provide evidence-based treatments to patients, helping physicians and consumers make informed healthcare choices.
Researchers found that pressure-lowering eye drops reduced the development of primary open-angle glaucoma by more than 50% in high-risk individuals. The study also highlighted personal and ocular risk factors associated with glaucoma development.
A survey found that few Americans are aware of ocular hypertension, with only 41% recognizing it as a factor in glaucoma risk. Many individuals over 40 years old are unaware they need routine screening for the condition, despite being at increased risk.
A recent study found that eye drops can delay the onset of glaucoma by reducing intraocular pressure by approximately 20%. The Ocular Hypertension Treatment Study (OHTS) followed 1,636 participants with elevated eye pressure and showed a significant reduction in glaucoma development among those who received treatment. This breakthrough...
A new family of chloride ion channels has been identified in humans, which causes hereditary eye disorders. The discovery was made by a team of researchers at the Howard Hughes Medical Institute and found at least three other members of this channel family in humans, four in fruit flies, and 24 in the worm Caenorhabditis elegans.
A team of researchers has discovered that the medial superior temporal area (MST) acts as both a compass and biological global positioning system, providing mental maps to help understand location and movement. This finding helps explain why people with Alzheimer's disease struggle to navigate their environment.
A randomized trial comparing atropine eye drops and patching found that atropine improved visual acuity by 74%, while parents preferred this treatment method. The study addressed the long-standing debate about which method is better, providing valuable insights for doctors and researchers.
Researchers from the Office of Naval Research have developed a retinal microchip to restore vision in the blind. The chip electronically stimulates healthy retina cells, transmitting signals to the brain to recognize faces and read large text.
A study published in Archives of Ophthalmology found that glaucoma affects approximately 0.5% of people aged 41-49 and up to 12% of those aged 80+, with women being disproportionately affected. The high prevalence among Mexican-Americans may be attributed to barriers such as cost of care and distrust of majority culture.
A new Mayo Clinic study has found that a widely accepted treatment for Graves' ophthalmopathy shows no benefits in improving symptoms. Researchers conducted a double-blind study and discovered no difference between treated and untreated eyes after three or six months, casting doubt on the effectiveness of this long-used treatment.
A recent study by Ohio State University found that survival rates are similar for patients with choroidal melanoma who undergo radiation therapy or have their affected eye removed. The study, which involved 1,317 patients, showed that both treatment options result in high five-year survival rates.
Researchers found that triclosan is effective against malaria and toxoplasmosis parasites at low concentrations, without harming host cells. The study suggests combining triclosan with other inhibitors to disrupt fatty acid synthesis and prevent resistant microbes.
A study of 50 patients found that almost twice as many preferred disposable extended-wear lenses due to their convenience. The subjects reported no differences in vision, comfort, or eye health between the two types of lenses.
Researchers have identified the three-dimensional atomic structure of a critical gene-regulating molecule, revealing its importance in human diseases such as cancers, autoimmune disorders, and developmental disorders. The discovery could lead to the development of new treatments and therapies for these conditions.
Eye attacks, also known as Ischematic Optic Neuropathy (ION), are a sudden lack of blood flow to the eye resulting in painless but catastrophic consequences. A new multi-center clinical trial aims to determine whether neuro-protection can minimize collateral damage and prevent second eye involvement.
The Early Treatment for Retinopathy of Prematurity (ETROP) study demonstrated that premature infants who receive early treatment have better vision outcomes compared to waiting until the traditional treatment threshold. The study also established a new risk assessment model to identify high-risk infants, reducing poor visual outcomes a...
Researchers found a set of neurons in the supplementary eye field that react when an individual realizes they made a mistake, shedding light on self-control and cognitive processes. This discovery has implications for understanding schizophrenia, obsessive-compulsive disorder, and psychopathic behavior.
A new operation developed at Johns Hopkins improves vision for nearly half of the first 100 patients treated with early-stage macular degeneration. Six months after surgery, 48% of patients could read an additional two lines on a standard eye chart or had vision of 20/100 or better, enough to legally drive in Maryland.